Last reviewed · How we verify
AM-111
At a glance
| Generic name | AM-111 |
|---|---|
| Sponsor | Auris Medical AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AM-111 in the Treatment of Acute Inner Ear Hearing Loss (PHASE3)
- Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (PHASE3)
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain (PHASE3)
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation (PHASE3)
- Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss (PHASE2)
- Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AM-111 CI brief — competitive landscape report
- AM-111 updates RSS · CI watch RSS
- Auris Medical AG portfolio CI